This study reports that a newly discovered immune checkpoint, ITPRIPL1, can also be leveraged as a proteomic biomarker for tumor diagnosis, prognosis prediction, and relation to CD8+ T cell infiltration. This evidence concerns the gene CD8A and neoplasm.